Skip to main content
. 2010 Nov 1;28(31):4762–4768. doi: 10.1200/JCO.2010.30.3545

Table 3.

Summary of the Toxicities Associated With Vandetanib After the First 6 Weeks of Therapy

Toxicity Dosage Level
1: 50 mg/m2(n = 3)Grades 1 and 2 2: 65 mg/m2 (n = 3)
3: 85 mg/m2(n = 2)*Grades 1 and 2 4: 110 mg/m2(n = 14)*
5: 145 mg/m2(n = 8)*
Grades 1 and 2 Grade 3 Grades 1 and 2 Grade 3 Grades 1 and 2 Grade 3 Grade 4
Lymphopenia 2 2 1 2 9 1 3 0 1
Neutropenia 0 0 0 0 3 0 1 0 0
Proteinuria 2 2 0 2 10 0 6 0 0
Hypertension 0 0 0 1 6 0 2 1 0
Hypokalemia 1 1 0 0 0 0 3 1 0
Hypophosphatemia 0 1 0 0 1 0 2 0 0
Prolonged QTc interval 1 1 0 1 6 0 4 0 0
Increase in aminotransferases 0 1 0 1 6 0 3 0 0
Fatigue 0 1 0 0 6 0 2 0 0
Skin rash 2 2 0 1 5 0 2 0 0
Photosensitivity 0 0 0 0 0 1 0 0 0
Vomiting 2 2 0 1 6 0 3 0 0
Diarrhea 0 2 0 0 5 0 2 1 0
Mucositis 0 0 0 0 1 0 0 0 0
Anorexia 0 1 0 0 6 0 3 0 0
*

Five patients (one at dosage level 3, and two each at dosage levels 4 and 5) did not receive vandetanib after the dose-limiting toxicity evaluation period because of toxicity (n = 3), leptomeningeal disease progression (n = 1), and withdrawal of consent (n = 1).

Grade 1 hypertension was excluded.

HHS Vulnerability Disclosure